2009.10.01 Weekly Broadcast Email

 
The following updates were made to the website for the week of September 28, 2009.
________________________________________
Annual Meeting:
Thank you to everyone for making the Annual Research Base Meeting in Asheville, NC a great success! The meeting handouts and presentations can be found on the annual meeting section of our website. We look forward to seeing you all again next year in Wilmington, NC.

Note: The link for part 2 of Saturday’s presentations will be live tomorrow morning. All other links are functioning.
________________________________________
Adverse Events:
The following adverse events were reported during the month of September. A PDF of the AE document has been attached to this email and a summary of the event can be found on the adverse event page of the website.
98308: 31
97202: 34
91105: 6
________________________________________
Accrual Totals:
In the month of September, 8 patients were accrued to CCCWFU CCOP Research Base trials. SCCC was the top accruing site with 4 patients. See the Research Base home page for further information.
________________________________________
97202 Randomized Double-Blind Placebo-Controlled Study of Oral Coenzyme Q10 to Relieve Self-Reported Cancer Treatment Related Fatigue in Breast Cancer Patients
2009 CR Approval Letter added to the website.
________________________________________
Featured Study: Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients

Have you considered opening 91105 at your site? Has your site accrued patients to this study recently? You might be interested to know…

Several recent protocol changes have been made to study 91105, Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients. These changes were made to facilitate and simplify enrollment which include:
-Adding a $40 gift for participating
-Simplifying and reducing medication exclusions
Visit the recently updated 91105 webpage to view:
• Letter from the PI, Dr. Steve Rapp
• Brochure outlining recent changes
• Training video
________________________________________
Reminder:
97106 (Randomized Study to Determine whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors) only has 10 minority accrual slots open for patient accruals. We would like to see this study close by the end of the summer, so if you have patients that may be eligible for this study, please try and get them registered by then.

Thank you,

Lisa Hawkins
Wake Forest University Baptist Medical Center
Department of Radiation Oncology
Research Base Protocol Information Office
2000 West First Street, Suite 401
Winston-Salem, NC 27104
Phone: 336-716-0891
Pager: 336-716-2440, ID number 1689
Fax: 336-716-6275

Quick Reference

Research Base

Fax 336-716-6275
Phone 336-716-0891

2000 West First Street
Protocol Information Office
Suite 101
Winston-Salem, NC 27104
Find A Doctor Ways to Give
Last Updated: 10-21-2009
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.